Aberdeen Group plc cut its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 99.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,425 shares of the biotechnology company's stock after selling 2,834,692 shares during the quarter. Aberdeen Group plc's holdings in uniQure were worth $324,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Orbimed Advisors LLC increased its holdings in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock worth $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Two Seas Capital LP acquired a new stake in uniQure during the third quarter worth $31,988,000. Assenagon Asset Management S.A. increased its position in shares of uniQure by 249.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company's stock worth $23,653,000 after purchasing an additional 366,781 shares during the last quarter. Maverick Capital Ltd. raised its holdings in uniQure by 5.4% in the 1st quarter. Maverick Capital Ltd. now owns 697,640 shares of the biotechnology company's stock valued at $11,406,000 after buying an additional 35,820 shares during the period. Finally, Readystate Asset Management LP raised its holdings in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company's stock valued at $8,252,000 after buying an additional 143,142 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. HC Wainwright lowered their price objective on shares of uniQure from $80.00 to $65.00 and set a "buy" rating for the company in a research report on Wednesday. Barclays downgraded shares of uniQure from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $60.00 to $28.00 in a report on Monday, October 5th. Royal Bank Of Canada cut their target price on uniQure from $65.00 to $48.00 and set an "outperform" rating on the stock in a research report on Friday, October 2nd. Wolfe Research raised uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $55.58.
Check Out Our Latest Stock Analysis on uniQure
Latest uniQure News
These are some of the QURE news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its estimates for FY2026 and FY2027, as well as several quarterly forecasts, indicating smaller expected losses. The firm kept its Buy rating. Analyst estimate details
- Neutral Sentiment: Analyst coverage cited an average price target of $56.83, though that figure alone does not indicate a new change in sentiment. Average price target report
- Negative Sentiment: HC Wainwright cut its price target to $65 and lowered its FY2029 and FY2030 earnings estimates, tempering the more favorable near-term revisions. It nevertheless retained its Buy rating. Price target report Target cut coverage
uniQure Stock Performance
Shares of uniQure stock opened at $19.35 on Friday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -5.51 and a beta of 1.14. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $51.72. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. The firm's 50 day moving average is $27.05 and its two-hundred day moving average is $29.58.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. The company had revenue of $5.20 million for the quarter, compared to analysts' expectations of $6.17 million. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. Research analysts forecast that uniQure N.V. will post -3.79 EPS for the current fiscal year.
About uniQure
(
Free Report)
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients' cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington's disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
Featured Articles
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.